How regulators have adapted globally to clinical trials for drugs and biologics during the COVID-19 crisis

The COVID-19 pandemic has disrupted clinical trials globally and has resulted in a 65% worldwide decrease in new patient enrollment year-over-year during March 2020. As a result, regulators across the globe have issued new guidances to support the industry in their hour of need.